Sage Therapeutics, Inc.
SAGE
$6.68
-$0.07-1.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.21M | -95.78M | -93.55M | -102.85M | -108.48M |
| Total Depreciation and Amortization | 112.00K | 129.00K | 255.00K | 311.00K | 336.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.81M | 8.33M | 12.11M | 15.12M | 12.12M |
| Change in Net Operating Assets | -25.44M | 20.76M | -1.18M | 6.99M | 58.19M |
| Cash from Operations | -81.73M | -66.56M | -82.37M | -80.44M | -37.83M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 45.78M | 46.57M | 81.05M | -386.00K | 139.44M |
| Cash from Investing | 45.78M | 46.57M | 81.05M | -386.00K | 139.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 242.00K | -- | 1.44M | 8.19M | 1.56M |
| Repurchase of Common Stock | -94.00K | -2.00K | -399.00K | -1.00K | -2.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -117.00K | -- |
| Cash from Financing | 148.00K | -2.00K | 1.04M | 8.07M | 1.56M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.80M | -19.99M | -274.00K | -72.75M | 103.16M |